Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription 25.02.2019 1 BMC Cancer 1 Cancer Cell 1 Cancer Chemother Pharmacol 2 Cancer Epidemiol Biomarkers Prev 2 Clin Exp Metastasis 2 Clin Nucl Med 1 Eur J Cancer 2 Hum Pathol 1 Int J Cancer 1 J Clin Oncol 1 J Immunol 1 J Natl Cancer Inst 10 J Thorac Oncol 1 JAMA Oncol 1 Lancet Respir Med 1 Lung Cancer 1 Lung Cancer (Auckl) 1 Mol Carcinog 6 Oncogene 5 PLoS One 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Cancer

1. BERGAMINO M, Rullan AJ, Saigi M, Peiro I, et al
   Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
   BMC Cancer. 2019;19:165.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Cell

2. LUKEY MJ, Katt WP, Cerione RA
   Targeting Therapy Resistance: When Glutamine Catabolism Becomes Essential.
   Cancer Cell. 2018;33:795-797.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Chemother Pharmacol

3. MATHERLY LH, Hou Z, Gangjee A
   The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.
   Cancer Chemother Pharmacol. 2018;81:1-15.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Epidemiol Biomarkers Prev

4. PALAZZO LL, Sheehan DF, Tramontano AC, Kong CY, et al
   Disparities and Trends in Rates of Genetic Testing and Erlotinib Treatment Among Metastatic Non-Small Cell Lung Cancer Patients.
   Cancer Epidemiol Biomarkers Prev. 2019 Feb 20. pii: 1055-9965.EPI-18-0917.
   PubMed     Text format     Abstract available
   
   
5. ZHAO Y, Varn FS, Cai G, Xiao F, et al
   A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.
   Cancer Epidemiol Biomarkers Prev. 2018;27:86-95.
   PubMed     Text format     Abstract available
   
   

   
   Clin Exp Metastasis

6. GAREAU AJ, Brien C, Gebremeskel S, Liwski RS, et al
   Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
   Clin Exp Metastasis. 2018 Jan 11. pii: 10.1007/s10585-018-9874.
   PubMed     Text format     Abstract available
   
   
7. TAYLOR MD, Bollt O, Iyer SC, Robertson GP, et al
   Metastasis suppressor 1 (MTSS1) expression is associated with reduced in-vivo metastasis and enhanced patient survival in lung adenocarcinoma.
   Clin Exp Metastasis. 2018;35.
   PubMed     Text format     Abstract available
   
   

   
   Clin Nucl Med

8. SHAO F, Zhou D, Lan X
   Increased 99mTc Pertechnetate Uptake But Unimpressive 131I Activity in the Metastatic Mediastinal Lymph Nodes in a Thyroid Cancer Patient.
   Clin Nucl Med. 2018 Dec 3. doi: 10.1097/RLU.0000000000002405.
   PubMed     Text format     Abstract available
   
   
9. LAI YC, Wu YC, Kao CH, Hsieh TC, et al
   Peritoneal Deciduoid Malignant Mesothelioma on 67Ga SPECT/CT.
   Clin Nucl Med. 2018 Nov 3. doi: 10.1097/RLU.0000000000002363.
   PubMed     Text format     Abstract available
   
   

   
   Eur J Cancer

10. RATHOD S, Jeremic B, Dubey A, Giuliani M, et al
    Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials.
    Eur J Cancer. 2019;110:110-119.
    PubMed     Text format     Abstract available
    
    

    
    Hum Pathol

11. XING D, Banet N, Sharma R, Vang R, et al
    Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
    Hum Pathol. 2018;72:160-166.
    PubMed     Text format     Abstract available
    
    
12. ZHANG J, Sun J, Zhang Z, Liang X, et al
    Protein overexpression and gene amplification of cellular mesenchymal-epithelial transition factor is associated with poor prognosis in micropapillary-predominant subtype pulmonary adenocarcinoma.
    Hum Pathol. 2018;72:59-65.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

13. LEUNG EL, Luo LX, Li Y, Liu ZQ, et al
    Identification of a new inhibitor of KRAS-PDEdelta interaction targeting KRAS mutant non-small cell lung cancer.
    Int J Cancer. 2019 Feb 20. doi: 10.1002/ijc.32222.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

14. READY N, Hellmann MD, Awad MM, Otterson GA, et al
    First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
    J Clin Oncol. 2019 Feb 20:JCO1801042. doi: 10.1200/JCO.18.01042.
    PubMed     Text format     Abstract available
    
    

    
    J Immunol

15. NOSAKA T, Baba T, Tanabe Y, Sasaki S, et al
    Alveolar Macrophages Drive Hepatocellular Carcinoma Lung Metastasis by Generating Leukotriene B4.
    J Immunol. 2018;200:1839-1852.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

16. PIETRANTONIO F, Di Nicolantonio F, Schrock AB, Lee J, et al
    ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

17. RAMAEKERS B, De Ruysscher D
    Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?
    J Thorac Oncol. 2019;14:326-327.
    PubMed     Text format    
    
    
18. FERRARA R, Caramella C, Besse B, Champiat S, et al
    Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
    J Thorac Oncol. 2019;14:328-331.
    PubMed     Text format    
    
    
19. LAM S
    Lung Cancer Screening in Never-Smokers.
    J Thorac Oncol. 2019;14:336-337.
    PubMed     Text format    
    
    
20. LIZEE T, Basch E, Tremolieres P, Voog E, et al
    Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.
    J Thorac Oncol. 2019 Feb 15. pii: S1556-0864(19)30113.
    PubMed     Text format     Abstract available
    
    
21. LEE J, Maeng CH, Song JU
    The Role of Prophylactic Cranial Irradiation in Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2019;14:e60-e61.
    PubMed     Text format    
    
    
22. KOGURE Y, Ishii Y, Oki M
    Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    J Thorac Oncol. 2019;14:e55-e57.
    PubMed     Text format    
    
    
23. SALVI S, Ravetti JL, Arena G, Musso C, et al
    Evaluation of RET Gene Rearrangement by Fluorescence In Situ Hybridization in Malignant Mesothelioma.
    J Thorac Oncol. 2018;13:e12-e14.
    PubMed     Text format    
    
    
24. NEGRAO MV, Lam VK, Reuben A, Rubin ML, et al
    PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.
    J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30116.
    PubMed     Text format     Abstract available
    
    
25. AHN MJ
    Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?
    J Thorac Oncol. 2018;13:10-11.
    PubMed     Text format    
    
    
26. HENDRIKS LEL, Henon C, Auclin E, Mezquita L, et al
    Outcome of non-small cell lung cancer patients with brain metastases treated with checkpoint inhibitors.
    J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30117.
    PubMed     Text format     Abstract available
    
    

    
    JAMA Oncol

27. PALMA DA, Nguyen TK, Louie AV, Malthaner R, et al
    Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
    JAMA Oncol. 2019 Feb 21. pii: 2725402. doi: 10.1001/jamaoncol.2018.6993.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Respir Med

28. ROSELL R, Karachaliou N
    Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma.
    Lancet Respir Med. 2018;6:649-651.
    PubMed     Text format    
    
    

    
    Lung Cancer

29. CHEN Y, Chen B, Zhu X, Zhong J, et al
    A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
    Lung Cancer. 2018;116:96-98.
    PubMed     Text format    
    
    

    
    Lung Cancer (Auckl)

30. KATE S, Chougule A, Joshi A, Noronha V, et al
    Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis.
    Lung Cancer (Auckl). 2019;10:1-10.
    PubMed     Text format     Abstract available
    
    

    
    Mol Carcinog

31. CHEN W, Do KC, Saxton B, Leng S, et al
    Inhibition of the hexosamine biosynthesis pathway potentiates cisplatin cytotoxicity by decreasing BiP expression in non-small cell lung cancer cells.
    Mol Carcinog. 2019 Feb 20. doi: 10.1002/mc.22992.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

32. TANG J, Chen H, Wong CC, Liu D, et al
    DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients.
    Oncogene. 2018 Mar 14. pii: 10.1038/s41388-018-0196.
    PubMed     Text format     Abstract available
    
    
33. KIM Y, Shiba-Ishii A, Nakagawa T, Iemura SI, et al
    Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma.
    Oncogene. 2018;37:5387-5402.
    PubMed     Text format     Abstract available
    
    
34. WEEDEN CE, Ah-Cann C, Holik AZ, Pasquet J, et al
    Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
    Oncogene. 2018;37:4475-4488.
    PubMed     Text format     Abstract available
    
    
35. YUE J, Lv D, Wang C, Li L, et al
    Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3.
    Oncogene. 2018;37:4300-4312.
    PubMed     Text format     Abstract available
    
    
36. CHEN A, Sceneay J, Godde N, Kinwel T, et al
    Intermittent hypoxia induces a metastatic phenotype in breast cancer.
    Oncogene. 2018 May 1. pii: 10.1038/s41388-018-0259.
    PubMed     Text format     Abstract available
    
    
37. ITOH H, Kadomatsu T, Tanoue H, Yugami M, et al
    TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.
    Oncogene. 2018;37:2903-2920.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

38. WATANABE K, Yasumoto A, Amano Y, Kage H, et al
    Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor.
    PLoS One. 2018;13:e0203625.
    PubMed     Text format     Abstract available
    
    
39. LI Y, Appius A, Pattipaka T, Feyereislova A, et al
    Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.
    PLoS One. 2019;14:e0212831.
    PubMed     Text format     Abstract available
    
    
40. SCHREUDER A, Jacobs C, Gallardo-Estrella L, Prokop M, et al
    Predicting all-cause and lung cancer mortality using emphysema score progression rate between baseline and follow-up chest CT images: A comparison of risk model performances.
    PLoS One. 2019;14:e0212756.
    PubMed     Text format     Abstract available
    
    
41. JEON SM, Kwon JW, Choi SH, Park HY, et al
    Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015.
    PLoS One. 2019;14:e0212878.
    PubMed     Text format     Abstract available
    
    
42. MAGUIRE FB, Morris CR, Parikh-Patel A, Cress RD, et al
    A text-mining approach to obtain detailed treatment information from free-text fields in population-based cancer registries: A study of non-small cell lung cancer in California.
    PLoS One. 2019;14:e0212454.
    PubMed     Text format     Abstract available
    
    

    
    Thorax

43. BARCLAY ME, Lyratzopoulos G, Walter FM, Jefferies S, et al
    Incidence of second and higher order smoking-related primary cancers following lung cancer: a population-based cohort study.
    Thorax. 2019 Feb 18. pii: thoraxjnl-2018-212456.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: